[go: up one dir, main page]

FR3121360B1 - Formulation pour la délivrance d’ARN messager - Google Patents

Formulation pour la délivrance d’ARN messager Download PDF

Info

Publication number
FR3121360B1
FR3121360B1 FR2103254A FR2103254A FR3121360B1 FR 3121360 B1 FR3121360 B1 FR 3121360B1 FR 2103254 A FR2103254 A FR 2103254A FR 2103254 A FR2103254 A FR 2103254A FR 3121360 B1 FR3121360 B1 FR 3121360B1
Authority
FR
France
Prior art keywords
formulation
messenger rna
delivery
lipid nanoparticles
nanoemulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2103254A
Other languages
English (en)
Other versions
FR3121360A1 (fr
Inventor
Y Garcia Fabrice Navarro
Patrice Marche
Adrien Nougarede
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Institut National de la Sante et de la Recherche Medicale INSERM
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique CEA, Institut National de la Sante et de la Recherche Medicale INSERM, Commissariat a lEnergie Atomique et aux Energies Alternatives CEA filed Critical Commissariat a lEnergie Atomique CEA
Priority to FR2103254A priority Critical patent/FR3121360B1/fr
Priority to PCT/EP2022/058466 priority patent/WO2022207736A1/fr
Priority to EP22719866.0A priority patent/EP4312989A1/fr
Publication of FR3121360A1 publication Critical patent/FR3121360A1/fr
Application granted granted Critical
Publication of FR3121360B1 publication Critical patent/FR3121360B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulation pour la délivrance d’ARN messager L’invention concerne une formulation sous forme de nanoémulsion, comprenant une phase aqueuse continue et au moins une phase dispersée sous forme de nanoparticules lipidiques dans laquelle au moins un ARN messager est complexé à la surface des nanoparticules lipidiques, son procédé de préparation et ses utilisations pour la prévention et/ou le traitement d’une maladie. Figure pour l'abrégé : 1
FR2103254A 2021-03-30 2021-03-30 Formulation pour la délivrance d’ARN messager Active FR3121360B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR2103254A FR3121360B1 (fr) 2021-03-30 2021-03-30 Formulation pour la délivrance d’ARN messager
PCT/EP2022/058466 WO2022207736A1 (fr) 2021-03-30 2022-03-30 Formulation pour la délivrance d'arn messager
EP22719866.0A EP4312989A1 (fr) 2021-03-30 2022-03-30 Formulation pour la délivrance d'arn messager

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2103254 2021-03-30
FR2103254A FR3121360B1 (fr) 2021-03-30 2021-03-30 Formulation pour la délivrance d’ARN messager

Publications (2)

Publication Number Publication Date
FR3121360A1 FR3121360A1 (fr) 2022-10-07
FR3121360B1 true FR3121360B1 (fr) 2024-05-31

Family

ID=75850360

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2103254A Active FR3121360B1 (fr) 2021-03-30 2021-03-30 Formulation pour la délivrance d’ARN messager

Country Status (3)

Country Link
EP (1) EP4312989A1 (fr)
FR (1) FR3121360B1 (fr)
WO (1) WO2022207736A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2830596B1 (fr) * 2012-03-29 2020-12-30 Translate Bio, Inc. Nanoparticules neutres dérivées de lipides
FR2994849B1 (fr) 2012-08-30 2015-01-02 Commissariat Energie Atomique Formulation pour la delivrance de sequences nucleotidiques susceptibles de moduler des mecanismes endogenes d'arn interferents

Also Published As

Publication number Publication date
EP4312989A1 (fr) 2024-02-07
FR3121360A1 (fr) 2022-10-07
WO2022207736A1 (fr) 2022-10-06

Similar Documents

Publication Publication Date Title
Salem et al. Liposomal flucytosine capped with gold nanoparticle formulations for improved ocular delivery
Svetlichny et al. Solid lipid nanoparticles containing copaiba oil and allantoin: development and role of nanoencapsulation on the antifungal activity
HUP0102039A2 (hu) Albuminnal stabilizált paclitaxel alkalmazása tömör tumorok kezelésére szolgáló gyógyszerkészítmények előállítására, és a kapott gyógyszerkészítmények
Schnichels et al. Improved treatment options for glaucoma with brimonidine-loaded lipid DNA nanoparticles
Karn-Orachai et al. Surfactant effect on the physicochemical characteristics of γ-oryanol-containing solid lipid nanoparticles
Raoult et al. Ciprofloxacin therapy for Mediterranean spotted fever
JP7716996B2 (ja) 薬剤を含む水性組成物のｐＨを安定化させるための方法
US20230263907A1 (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
KR20120049267A (ko) 치료 방법
FR3121360B1 (fr) Formulation pour la délivrance d’ARN messager
Ban et al. Reduction of focal sweating by lipid nanoparticle-delivered myricetin
CA2427375A1 (fr) Composition pharmaceutique de dronedarone pour administration parenterale
JPH08175985A (ja) 点眼剤
Sanarova et al. Using polysorbates to create parenteral dosage forms of hydrophobic substances (a review)
Tonglairoum et al. Development and evaluation of N-naphthyl-N, O-succinyl chitosan micelles containing clotrimazole for oral candidiasis treatment
JP3889037B2 (ja) コリノイドと合成油脂または植物油脂とからなる、皮膚疾病を局所治療するための外用医薬組成物
Almeida et al. Nanoparticles in Ocular Drug Delivery Systems
Lamoudi et al. Fusidic acid microemulsion based on a pseudoternary phase diagram: development, characterization, and evaluation
JP7629392B2 (ja) グリチルリチンを含む組成物およびその化粧品および医薬品使用
TNSN98124A1 (fr) Compositions de sertraline solubilisee
EP1419762A1 (fr) Procédé de traitement des peaux grasses basé sur l'application d'une composition comprenant une charge composite silice-alumine et un hydrocolloide épaississant
Papavasiliou et al. Clinical outcomes of aneurysmal subarachnoid hemorrhage patients treated with oral diltiazem and limited intensive care management
Rezaei et al. Corrigendum to “Encapsulation of an endostatin peptide in liposomes: Stability, release, and cytotoxicity study”[Colloids Surf. B Biointerfaces 185 (October)(2019) 110552]
JPH0597660A (ja) 多重層エマルシヨンおよびその製造方法
FR3115992B1 (fr) Composition sous forme d'émulsion comprenant des saponines et une huile végétale

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20221007

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5